Eli Lil­ly plots NDA as sec­ond JAK study backs baric­i­tinib for alope­cia area­ta; Al­ny­lam heads to FDA af­ter full vutrisir­an da­ta pan out

Eli Lil­ly has post­ed pos­i­tive da­ta from its sec­ond Phase III study test­ing its JAK in­hibitor baric­i­tinib in spurring hair re­growth among pa­tients suf­fer­ing from se­vere alope­cia area­ta.

In­ves­ti­ga­tors re­port­ed a dose-de­pen­dent re­sponse to the drug, with 35% of the sub­jects in the 4 mg arm achiev­ing 80% or more scalp hair cov­er­age against 22% in the 2 mg arm. That’s in line with the first Phase III read­out.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER